Else Marit Inderberg leads the Translational Research Unit performing immunomonitoring in clinical trials and development of cellular therapy at the Dept. of Cellular therapy, Oslo University Hospital
Her main research focus is on T-cell function and therapy development, including identification of predictive biomarkers of therapy response. She has broad oncology-related clinical trial experience and holds an MSc equivalent degree in Immunology from France and a PhD in tumour immunology from the University of Oslo, Norway. She has co-authored numerous peer-reviewed publications, holds several patents, and is co-founder of two spin-off companies within cancer vaccination and cell therapy.
